119 related articles for article (PubMed ID: 25082681)
1. Central command.
Leslie M
Science; 2014 Aug; 345(6196):506-7. PubMed ID: 25082681
[No Abstract] [Full Text] [Related]
2. CX-5461 inhibits RNA Pol I in blood cancers.
Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
[TBL] [Abstract][Full Text] [Related]
3. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
4. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
5. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
[TBL] [Abstract][Full Text] [Related]
7. Targeting the nucleolus for cancer intervention.
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2014 Jun; 1842(6):802-16. PubMed ID: 24389329
[TBL] [Abstract][Full Text] [Related]
8. Targeting the nucleolus for cancer-specific activation of p53.
Drygin D; O'Brien SE; Hannan RD; McArthur GA; Von Hoff DD
Drug Discov Today; 2014 Mar; 19(3):259-65. PubMed ID: 23993916
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
10. Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis.
Achiron A; Mashiach R; Zilkha-Falb R; Meijler MM; Gurevich M
J Neuroimmunol; 2013 Oct; 263(1-2):91-7. PubMed ID: 23998422
[TBL] [Abstract][Full Text] [Related]
11. Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.
Prosser KE; Leung AWY; Harrypersad S; Lewis AR; Bally MB; Walsby CJ
Chemistry; 2018 Apr; 24(24):6334-6338. PubMed ID: 29490115
[TBL] [Abstract][Full Text] [Related]
12. The Selective RNA Polymerase I Inhibitor CX-5461 Mitigates Neointimal Remodeling in a Modified Model of Rat Aortic Transplantation.
Dai C; Sun M; Wang F; Zhu J; Wei Y; Guo X; Ma S; Dong B; Wang G; Jiang F; Wang J
Transplantation; 2018 Oct; 102(10):1674-1683. PubMed ID: 30247451
[TBL] [Abstract][Full Text] [Related]
13. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer.
Drygin D; Rice WG; Grummt I
Annu Rev Pharmacol Toxicol; 2010; 50():131-56. PubMed ID: 20055700
[TBL] [Abstract][Full Text] [Related]
14. Targeting RNA polymerase I transcription and the nucleolus for cancer therapy.
Hannan RD; Drygin D; Pearson RB
Expert Opin Ther Targets; 2013 Aug; 17(8):873-8. PubMed ID: 23862680
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ; Poortinga G; Sanij E; Hein N; Peck A; Cullinane C; Wall M; Cluse L; Drygin D; Anderes K; Huser N; Proffitt C; Bliesath J; Haddach M; Schwaebe MK; Ryckman DM; Rice WG; Schmitt C; Lowe SW; Johnstone RW; Pearson RB; McArthur GA; Hannan RD
Cancer Cell; 2012 Jul; 22(1):51-65. PubMed ID: 22789538
[TBL] [Abstract][Full Text] [Related]
16. Natural products inducing nucleolar stress: implications in cancer therapy.
Wu M; Lu L; Chen S; Li Y; Zhang Q; Fu S; Deng X
Anticancer Drugs; 2022 Jan; 33(1):e21-e27. PubMed ID: 34561998
[TBL] [Abstract][Full Text] [Related]
17. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
18. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
[TBL] [Abstract][Full Text] [Related]
19. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity.
Kumar V; Jaggi M; Singh AT; Madaan A; Sanna V; Singh P; Sharma PK; Irchhaiya R; Burman AC
Eur J Med Chem; 2009 Aug; 44(8):3356-62. PubMed ID: 19361894
[TBL] [Abstract][Full Text] [Related]
20. The nucleolus: an emerging target for cancer therapy.
Hein N; Hannan KM; George AJ; Sanij E; Hannan RD
Trends Mol Med; 2013 Nov; 19(11):643-54. PubMed ID: 23953479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
